Virtual Biotech: Single-Cell-Supported Drug Targets Are 48% More Likely to Reach Market
james_y_zou · x · 2026-09-18
Follow-up on the Virtual Biotech study: agents annotated 57,000 clinical trials, curating scattered outcomes into an open standardized database. Analysis shows drug targets backed by single-cell evidence are 48% more likely to reach market, helping the industry prioritize targets.
More from Research
- Google Research uses generative UI to let teachers create learning interactives — gaganghotra_ · 2026-09-18
- New paper proposes foundation models that learn across biological scales — anshulkundaje · 2026-09-18
- Figure May Have Found a Scaling Law for Robot Pretraining, Predicting 8x-Data Runs — rohanpaul_ai · 2026-09-18
- STOC 2027 call for papers adds AI-era rules: mandatory public posting and required videos — fortnow · 2026-09-18
- Bend 2 launches: a proof-checking language that blocks AI coding mistakes, runs natively on GPUs — max_paperclips · 2026-09-18
- FLARE-AI paper proposes standardized flaw reporting system for deployed AI, seeking a full-time operator — huggingface · 2026-09-18